These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12091325)

  • 1. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells.
    Guimond M; Balassy A; Barrette M; Brochu S; Perreault C; Roy DC
    Blood; 2002 Jul; 100(2):375-82. PubMed ID: 12091325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process.
    Chen BJ; Cui X; Liu C; Chao NJ
    Blood; 2002 May; 99(9):3083-8. PubMed ID: 11964269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.
    Mielke S; Nunes R; Rezvani K; Fellowes VS; Venne A; Solomon SR; Fan Y; Gostick E; Price DA; Scotto C; Read EJ; Barrett AJ
    Blood; 2008 Apr; 111(8):4392-402. PubMed ID: 17878399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of host reactive T cells by photodynamic cell purging and prevention of graft versus host disease.
    Goggins TF; Chao N
    Leuk Lymphoma; 2003 Nov; 44(11):1871-9. PubMed ID: 14738138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host Disease.
    McIver ZA; Grayson JM; Coe BN; Hill JE; Schamerhorn GA; Ohulchanskyy TY; Linder MK; Davies KS; Weiner RS; Detty MR
    J Immunol; 2016 Sep; 197(5):1631-41. PubMed ID: 27456485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease.
    Bastien JP; Krosl G; Therien C; Rashkovan M; Scotto C; Cohen S; Allan DS; Hogge D; Egeler RM; Perreault C; Roy DC
    Blood; 2010 Dec; 116(23):4859-69. PubMed ID: 20798236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of small molecules immunosuppressants on P-glycoprotein activity and T-cell function.
    Llaudó I; Cassis L; Torras J; Bestard O; Franquesa Ml; Cruzado JM; Cerezo G; Castaño E; Pétriz J; Herrero-Fresneda I; Grinyó JM; Lloberas N
    J Pharm Pharm Sci; 2012; 15(3):407-19. PubMed ID: 22974789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.
    Perruccio K; Topini F; Tosti A; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2008; 40(1):76-83. PubMed ID: 17977031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
    Wehler TC; Nonn M; Brandt B; Britten CM; Gröne M; Todorova M; Link I; Khan SA; Meyer RG; Huber C; Hartwig UF; Herr W
    Blood; 2007 Jan; 109(1):365-73. PubMed ID: 16931626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.
    Mao C; Zhao Y; Li F; Li Z; Tian S; Debinski W; Ming X
    J Control Release; 2018 Sep; 286():289-300. PubMed ID: 30081143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function.
    Gupta S; Kim CH; Tsuruo T; Gollapudi S
    J Clin Immunol; 1992 Nov; 12(6):451-8. PubMed ID: 1363104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of alloreactive T cells using photodynamic therapy.
    Boumédine RS; Roy DC
    Cytotherapy; 2005; 7(2):134-43. PubMed ID: 16040392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential activity of P-glycoprotein in normal blood lymphocyte subsets.
    Ludescher C; Pall G; Irschick EU; Gastl G
    Br J Haematol; 1998 Jun; 101(4):722-7. PubMed ID: 9674746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression.
    Mu XY; Gosland MP; Bartik MM; Schimmelpfennig J; Kay NE
    J Clin Immunol; 1999 Jul; 19(4):239-46. PubMed ID: 10471978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection.
    Donnenberg VS; Burckart GJ; Zeevi A; Griffith BP; Iacono A; McCurry KR; Wilson JW; Donnenberg AD
    Transplantation; 2004 Jun; 77(11):1699-706. PubMed ID: 15201669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective photodepletion of malignant T cells in extracorporeal photopheresis with selenorhodamine photosensitizers.
    McIver ZA; Kryman MW; Choi Y; Coe BN; Schamerhorn GA; Linder MK; Davies KS; Hill JE; Sawada GA; Grayson JM; Detty MR
    Bioorg Med Chem; 2016 Sep; 24(17):3918-3931. PubMed ID: 27301678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
    Koh MB; Prentice HG; Lowdell MW
    Bone Marrow Transplant; 1999 May; 23(10):1071-9. PubMed ID: 10373075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
    Davies JK; Koh MB; Lowdell MW
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.
    Gonzalez M; Quezada SA; Blazar BR; Panoskaltsis-Mortari A; Rudensky AY; Noelle RJ
    J Immunol; 2002 Nov; 169(10):5581-9. PubMed ID: 12421935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease.
    Stuehler C; Mielke S; Chatterjee M; Duell J; Lurati S; Rueckert F; Einsele H; Bargou RC; Topp MS
    Blood; 2009 Sep; 114(13):2829-36. PubMed ID: 19657113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.